Robust Performance of the Novel Research-Use-Only Idylla GeneFusion Assay Using a Diverse Set of Pathological Samples with a Proposed 1-Day Workflow for Advanced NSCLC Evaluation
A range of different techniques are available for predictive biomarker testing for non-small-cell lung cancer (NSCLC) clinical management. International guidelines suggest next-generation sequencing (NGS) as the preferred procedure, but other reverse transcriptase-polymerase chain reaction (RT-PCR)-...
Main Authors: | Alvaro Leone, Lucia Anna Muscarella, Paolo Graziano, Andrea Tornese, Lucia Rosalba Grillo, Angela Di Lorenzo, Monica Bronzini, Stefania Scarpino, Angelo Sparaneo, Giulio Rossi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/1/292 |
Similar Items
-
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
by: Sara Elena Rebuzzi, et al.
Published: (2021-03-01) -
Oncogenic driver mutations in Vietnamese patients with lung adenocarcinoma
by: Linh Dieu Vuong, et al.
Published: (2023-08-01) -
NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
by: Anna Michelotti, et al.
Published: (2022-06-01) -
Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
by: Lorenza Pecciarini, et al.
Published: (2023-04-01) -
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
by: Daniele Marinelli, et al.
Published: (2022-10-01)